These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28353055)

  • 1. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.
    Vande Casteele N; Mould DR; Coarse J; Hasan I; Gils A; Feagan B; Sandborn WJ
    Clin Pharmacokinet; 2017 Dec; 56(12):1513-1523. PubMed ID: 28353055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.
    Wade JR; Parker G; Kosutic G; Feagen BG; Sandborn WJ; Laveille C; Oliver R
    J Clin Pharmacol; 2015 Aug; 55(8):866-74. PubMed ID: 25735646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol.
    Melmed GY; McGovern D; Schreiber S; Kosutic G; Spearman M; Coarse J; Sandborn WJ
    Curr Med Res Opin; 2016 Dec; 32(12):1937-1941. PubMed ID: 27494777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
    Lee SD; Rubin DT; Sandborn WJ; Randall C; Younes Z; Schreiber S; Schwartz DA; Burakoff R; Binion D; Dassopoulos T; Arsenescu R; Gutierrez A; Scherl E; Kayhan C; Hasan I; Kosutic G; Spearman M; Sen D; Coarse J; Hanauer S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1870-80. PubMed ID: 27400222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
    Loftus EV; Colombel JF; Schreiber S; Randall CW; Regueiro M; Ali T; Arendt C; Coarse J; Spearman M; Kosutic G
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1753-1762. PubMed ID: 27464588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.
    Sandborn WJ; Wolf DC; Kosutic G; Parker G; Schreiber S; Lee SD; Abraham B; Afzali A; Arsenescu RI; Gutierrez A; Spearman M; Coarse J; Feagan BG
    Inflamm Bowel Dis; 2017 Jul; 23(7):1047-1056. PubMed ID: 28410341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
    Vande Casteele N; Feagan BG; Vermeire S; Yassine M; Coarse J; Kosutic G; Sandborn WJ
    Aliment Pharmacol Ther; 2018 Jan; 47(2):229-237. PubMed ID: 29159893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
    Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
    Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations.
    Vadcharavivad S; Praisuwan S; Techawathanawanna N; Treyaprasert W; Avihingsanon Y
    J Clin Pharm Ther; 2016 Jun; 41(3):310-28. PubMed ID: 27191538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
    Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
    Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease.
    Wang Y; Marier JF; Lavigne J; Kassir N; Martin P
    J Clin Pharmacol; 2020 Jul; 60(7):903-914. PubMed ID: 32119128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS; Nelson M; Dolder CR
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
    N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
    Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
    Sandborn WJ; Melmed GY; McGovern DP; Loftus EV; Choi JM; Cho JH; Abraham B; Gutierrez A; Lichtenstein G; Lee SD; Randall CW; Schwartz DA; Regueiro M; Siegel CA; Spearman M; Kosutic G; Pierre-Louis B; Coarse J; Schreiber S
    Aliment Pharmacol Ther; 2015 Aug; 42(3):330-42. PubMed ID: 26031921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.